FibroGen Overview

Two innovative, first-in-class product platforms

- Pamrevlumab is the leader in anti-CTGF therapeutics
- Roxadustat is the leader in HIF-PHI therapeutics
A novel investigational agent for treating fibrotic and fibro-proliferative diseases

Fully human monoclonal antibody to connective tissue growth factor (CTGF), a central mediator of fibrosis

- Duchenne Muscular Dystrophy (DMD)
  - Phase 2 trial fully enrolled

- Idiopathic Pulmonary Fibrosis (IPF)
  - Positive Phase 2b safety and efficacy data presented at ERS 2017 and ATS 2018
  - Fast Track designation granted by FDA
  - Phase 3 trial design in progress – study start in 2019

- Pancreatic Cancer (LAPC)
  - Positive clinical data presented at ASCO 2018
  - Fast Track designation granted by FDA
  - Phase 3 trial design in progress – study start in 2019
Pamrevlumab DMD Program

Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to CTGF, in Non-Ambulatory Subjects with Duchenne Muscular Dystrophy

An open-label, single-arm study, in 21 non-ambulatory boys, age 12 years of age and older

• Objective: Estimate efficacy, evaluate safety and tolerability, and assess pharmacokinetics (PK)

• Endpoints:
  • Change in pulmonary function
  • Change in upper body muscle function tests
  • Change in muscle and cardiac fibrosis by MRI imaging

• Study Status: Fully enrolled and treatment is ongoing
Study FGCL-3019-079 Design

• Each subject is receiving IV infusions of pamrevlumab (35 mg/kg every 2 weeks, not to exceed 150 cc/hour) for up to 156 weeks
• All subjects are closely monitored for safety

Screening

Up to 4 weeks

Pamrevlumab (35 mg/kg, q2W)

156 weeks

Follow-up

2 weeks
Participating Centers

• UCSF Benioff Children's Hospital in San Francisco, CA
• Cincinnati Children’s in Cincinnati, OH
• Washington University in St. Louis, MO
• Children’s Hospital Colorado in Aurora, CO
• Rare Disease Research, Atlanta, GA
• Children’s Hospital in Philadelphia, PA
• Boston’s Children’s Hospital in Boston, MA
• Shriners Hospital for Children in Portland, OR
• UCLA School of Medicine in Los Angeles, CA
• Children’s Medical Center in Dallas, TX
Acknowledgements

• We would like to extend our appreciation to patients, their families, and the DMD community

• We would like to thank PPMD for the opportunity to participate
For additional information regarding this study and participating sites, please contact:

Jessica Charpentier, FibroGen Clinical Program Manager
jcharpentier@fibrogen.com
415-978-1346
or visit
www.clinicaltrials.gov (NCT02606136)
Thank You!